Summary of the Conference Call Record Company Overview - The document discusses **Zhaoyan New Drug**, a leading company in the domestic safety evaluation (安评) sector, focusing on its performance forecast for 2025 and the impact of various factors on its financial results [1][2]. Key Financial Metrics - **Revenue Forecast**: Zhaoyan New Drug expects to achieve revenue between **1.573 billion to 1.738 billion yuan** in 2025, representing a year-on-year decrease of approximately **13.9% to 22.1%** [1]. - **Net Profit**: The company anticipates a net profit attributable to shareholders of **233 million to 349 million yuan**, reflecting a significant year-on-year increase of about **214.0% to 371.0%** [1]. - **Non-recurring Net Profit**: The forecast for non-recurring net profit is approximately **246 million to 370 million yuan**, indicating a substantial increase of around **945.2% to 1,467.7%** year-on-year [1]. Core Insights - **Biological Assets Contribution**: The fair value changes of biological assets are expected to contribute approximately **452 million to 499 million yuan** to net profit, marking a significant turnaround from previous losses. This is driven by rising market prices and natural growth of the assets [1]. - **Laboratory Services Impact**: The net profit from laboratory services and other businesses is projected to be between **-206 million to -130 million yuan**, indicating a negative shift year-on-year due to intense competition in the industry [2]. Additional Important Points - **Market Dynamics**: Zhaoyan New Drug benefits from the digestion of existing orders and the transmission of new R&D demands to clinical CROs, alongside its unique integrated resources for experimental monkeys, which positions the company for further performance release [2].

Group 1 - Zhaoyan New Drug expects a net profit of approximately 233 million to 349 million yuan for 2025, representing a year-on-year increase of 214% to 371%, driven by rising market prices of biological assets and natural growth appreciation [1] - Kaiyin Technology has withdrawn its drug registration application for Peginterferon α-2 injection, resulting in a one-time asset impairment of 110 million yuan, significantly impacting its 2025 profit [2] - Qizheng Tibetan Medicine's subsidiary has received approval for its Shiwai Longdan Flower Capsule as a national second-level protected traditional Chinese medicine, providing a seven-year market exclusivity that will enhance its competitive position [3] Group 2 - GSK has reached a final agreement to acquire RAPT Therapeutics, focusing on innovative therapies for inflammation and immune diseases, with the deal expected to close in Q1 2026 [4] - Qilu Pharmaceutical has initiated a Phase I clinical trial for QLS5316, its first dual-target antibody-drug conjugate aimed at advanced solid tumors, marking a significant step in its innovation strategy [5]